News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Mersana Therapeutics, Inc. Awarded Patent With Broad Coverage For Fleximer-ADC Platform Technology


4/2/2014 9:55:20 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mersana Therapeutics, Inc., a biopharmaceutical company developing its Fleximer® antibody-drug conjugate (ADC) platform and therapeutics, today announced that it was awarded U.S. Patent No. 8,685,383, entitled “Protein-Polymer-Drug Conjugates.” This patent provides Mersana broad coverage for its polymer-based Fleximer-ADC platform technology. The patent covers Fleximer-drug conjugates that can be linked to an antibody to create next-generation antibody drug conjugates.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES